[1] |
CAMPANA D, COUSTAN-SMITH E.Detection of minimal residual disease in acute leukemia by flow cytometry[J]. Cytometry, 1999, 38(4): 139-152.
|
[2] |
KERST G,KREYENBERG H,ROTH C,et al.Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR[J]. Br J Haematol,2005,128(6):774-782.
|
[3] |
BOROWITZ MJ,WOOD BL,DEVIDAS M,et al.Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232[J]. Blood,2015,126(8):964-971.
|
[4] |
BENE MC,GRIMWADE D,HAFERLACH C,et al.Leukemia diagnosis:today and tomorrow[J]. Eur J Haematol,2015,95(4):365-373.
|
[5] |
KARAWAJEW L,DWORZAK M,RATEI R,et al.Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia[J]. Haematologica,2015,100(7):935-944.
|
[6] |
CAMPANA D,NEALE GA,COUSTAN-SMITH E,et al.Detection of minimal residual disease in acute lymphoblastic leukemia:the St Jude experience[J]. Leukemia,2001,15(2):278-279.
|
[7] |
LUCIO P,GAIPA G,VAN LOCHEM EG,et al.BIOMED-I concerted action report:flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia:international standardization and clinical evaluation[J]. Leukemia,2001,15(8):1185-1192.
|
[8] |
ORFAO A,CIUDAD J,LOPEZ-BERGES MC,et al.Acute lymphoblastic leukemia (ALL):detection of minimal residual disease (MRD) at flow cytometry[J]. Leuk Lymphoma,1994,13(Suppl 1):87-90.
|
[9] |
WEIR EG,COWAN K,LEBEAU P,et al.A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry:implications for residual disease detection[J]. Leukemia,1999,13(4):558-567.
|
[10] |
ZUR STADT U,HARMS DO,SCHLTER S,et al.MRD at the end of induction therapy in childhood acute lymphoblastic leukemia:outcome prediction strongly depends on the therapeutic regimen[J]. Leukemia,2001,15(2):283-285.
|
[11] |
DELLA PORTA MG,PICONE C,PASCUTTO C,et al.Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes:results of a European Leukemia NET study[J]. Haematologica,2012,97(8):1209-1217.
|
[12] |
BJRKLUND E,MAZUR J,SDERHLL S,et al.Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia[J]. Leukemia,2003,17(1):138-148.
|
[13] |
COUSTAN-SMITH E,SANCHO J,HANCOCK ML,et al.Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Blood,2000,96(8):2691-2696.
|
[14] |
DWORZAK MN,FRSCHL G,PRINTZ D,et al.Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia[J]. Blood, 2002,99(6):1952-1958.
|
[15] |
BOROWITZ MJ,PULLEN DJ,WINICK N,et al.Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia:implications for residual disease detection:a report from the children's oncology group[J]. Cytometry B Clin Cytom,2005,68(1):18-24.
|
[16] |
DWORZAK MN,GAIPA G,SCHUMICH A,et al.Modulation fo antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient:evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group[J].Cytometry B Clin Cytom,2010,78(3):147-153.
|
[17] |
GOMEZ E,SAN MIGUEL JF,GONZALEZ M,et al.Phenotypic changes in refractory and relapse acute lymphoblastic leukemias[J]. Sangre(Barc),1991,36(3):201-204.
|
[18] |
COUSTAN-SMITH E,SONG G,CLARK C,et al.New markers for minimal residual disease detection in acute lymphoblastic leukemia[J]. Blood,2011,117(23):6267-6276.
|
[19] |
SOLLY F,ANGELOT F,GARAND R,et al.CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry[J]. Cytometry A,2012,81(1):17-24.
|
[20] |
DJOKIC M,BJRKLUND E,BLENNOW E,et al.Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia[J]. Haematologica,2009,94(7):1016-1019.
|
[21] |
ARDJMAND A,DE BOCK CE,SHAHROKHI S,et al.Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia[J]. Hematology,2013,18(6):315-322.
|
[22] |
WAANDERS E,VAN DER VELDEN VH,VAN DER SCHOOT CE,et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia[J]. Leukemia,2011,25(2):254-258.
|
[23] |
MUZZAFAR T,MEDEIROS LJ,WANG SA,et al.Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry[J]. Am J Clin Pathol,2009,132(5):692-698.
|
[24] |
BARTRAM CR,SCHRAUDER A,KHLER R,et al.Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment[J]. Dtsch Arztebl Int,2012,109(40):652-658.
|
[25] |
IRVING J,JESSON J,VIRGO P,et al.Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting[J]. Haematologica,2009,94(6):870-874.
|